Skip to main content
HYUNDAI PHARMACEUTICAL CO., LTD logo

HYUNDAI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 004310 ISIN · KR7004310009 KO Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2025-02-12 Governance Information
Country KR South Korea
Listing KO 004310

About HYUNDAI PHARMACEUTICAL CO., LTD

http://www.hyundaipharm.co.kr/english

HYUNDAI PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, manufacturing, and distribution of pharmaceutical products, medical devices, and health-focused food and beverages. The company's portfolio encompasses a broad range of prescription (ETC) and over-the-counter (OTC) medicines. Key therapeutic areas include dermatology, respiratory and gastrointestinal disorders, as well as treatments for conditions such as hypertension and dementia. With a strong commitment to innovation, the company focuses on the research of new substances and the continuous development of its drug pipeline. It also serves as a strategic partner for global companies, facilitating market entry and collaboration through its business development initiatives.

Recent filings

Filing Released Lang Actions
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a regulatory disclosure from Hyundai Pharm regarding their 'Compliance Program' (CP) operations, detailing past performance and future plans. It is filed through the KRX (Korea Exchange) disclosure system as an 'Information Disclosure' (안내공시). Since it does not fit into specific financial reporting categories like 10-K or IR, and serves as a general regulatory update on corporate governance and compliance practices, it is best classified as a Regulatory Filing (RNS).
2025-02-12 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Hyundai Pharm. It outlines the date, location, agenda items (financial statements, director appointments, remuneration limits), and details regarding electronic voting. This document serves as the official notification and solicitation of shareholder participation for an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-02-12 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Hyundai Pharm Co., Ltd. It contains the meeting agenda, details on electronic voting, director activity reports, and financial statements (balance sheet, income statement, etc.) for the 61st fiscal period. While it contains financial data, it is primarily a proxy statement/notice for shareholders to inform them of the upcoming AGM and request their votes on specific agenda items. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2025-02-12 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is an official announcement from Hyundai Pharm regarding a decision on cash dividends. It specifies the dividend amount per share, the dividend record date, and the date of the board resolution. This fits the definition of a 'Notice of Dividend Amount' (DIV) as it provides specific details regarding dividend payments to shareholders.
2025-02-12 Korean
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory filing from Hyundai Pharm regarding the determination of a record date for cash and in-kind dividends. It specifies the record date (2025-03-05) and the purpose (confirming shareholders for dividends). While it relates to dividends, it is specifically a notice of the record date for dividend eligibility rather than the announcement of the dividend amount itself. Given the nature of the filing as a corporate action announcement regarding shareholder rights, it fits best under the 'DIV' (Notice of Dividend Amount) category as it is the primary regulatory disclosure for dividend-related events.
2025-02-12 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Hyundai Pharm regarding the approval of a Phase 3 clinical trial by the Ministry of Food and Drug Safety (MFDS). It is a 'Major Management Matter' disclosure (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a standard regulatory disclosure of a material business event, it falls under the 'Regulatory Filings' category.
2025-02-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.